DOCSLIB.ORG

Howcan Heat Illness Be Affected by Medications?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Howcan Heat Illness Be Affected by Medications? Howcan Heat Illness be affected byMedications? Certain medications increase the risk of These conditions include the following: This list is not exhaustive and is only a guide. Other heat illness by interfering with the body’s • Dementia medications, including many diuretics (water pills) and ability to sweat and cool (see lists below). • Nausea or vomiting prescription or over-the-counter antihistamines, can also This can lead to decreased heat tolerance • Parkinson’s increase your risk of heat illness. Further concerns should and increase the risk of heat illness. People • Psychiatric or emotional disorders like: be discussed with your health care professional. taking medications for certain medical Depression (with or without mania), conditions may be at an increased risk of Schizophrenia, Anxiety disorders Medication list originally developed by Osco Drug, and revised heat illness and should take the necessary • Seizures by the City of Milwaukee Health Department with input from the preventive measures. • Stomach, intestinal, or bladder spasms UW School of Pharmacy. Listing by GENERIC NAME Listing by BRAND NAME amitryptyline ........Elavil, Etrafon perphenazine...........Trilafon, Etrafon Abilify .................aripiprazole Homapin.............homotropine amoxapine ............Asendin phenelzine ...............Nardil Akineton .............biperiden Levbid.................hyoscyamine aripiprazole...........Abilify phenobarbital ..........Donnatal, Anafranil .............clomipramine Levsin.................hyoscyamine atropine & other ................................Barbidonna, Artane.................trihexyphenidyl Lithobid ..............lithium ................................Bellaphen, etc. belladonna Asendin ..............amoxapine Mellaril ...............thioridazine alkaloids* .............B&O prochlorperazine .....Compazine Atapryl................selegiline Moban ................molindone .............................suppositories, propantheline ..........Pro-Banthine Aventyl................nortryptyline Nardil..................phenelzine .............................Barbidonna, protryptyline............Vivactil .............................Bellaphen, B&O Navane ...............thiothixene quetiapine ...............Seroquel .............................Donnatal, etc. suppositories......belladonna alkaloids* Norpramin ..........desipramine risperidone..............Risperdal benztropine...........Cogentin Banthine .............methantreline Pamelor..............nortryptyline scopolamine............Transderm-Scop biperiden ..............Akineton Barbidonna .........belladonna alkaloids* Parnate ...............tranylcypromine selegiline.................Eldepryl, ...........................and phenobarbital butabarbital ..........Butibel, Fiorinal, ................................Carbex, Parsidol ..............ethopropazine ............................. Bellaphen............belladonna alkaloids* Fioricet, ................................Atapryl Phrenilin .............butalbital .............................Pyridium Plus ...........................and phenobarbital solifenacin...............VESIcare Pro-Banthine ......propantheline butalbital...............Phrenilin, Bentyl .................dicyclomine .............................Sedapap, thioridazine .............Mellaril Butibel ................butabarbital Prolixin ...............fluphenazine ............................Esgic, Fiortal, etc. thiothixene ..............Navane Cantil ..................mepenzolate Pyridium Plus.....butabarbital and ...........................hyoscyamine chlorpromazine.....Thorazine tolterodine...............Detrol Carbex ................selegiline Quarzan ..............clidinum clidinium...............Quarzan tranylcypromine ......Parnate Clozaril ...............clozapine Remeron.............mirtazapine clomipramine........Anafranil trifluoperazine .........Stelazine Cogentin ............benztropine Risperdal ............risperidone clozapine ..............Clozaril trihexyphenidyl........Artane Compazine..........prochlorperazine Robinul...............glycopyrrolate darifencacin ..........Enablex trimipramine ...........Surmontil Cystospaz ...........hyoscyamine Sanctura .............trospium desipramine..........Norpramin trospium .................Sanctura Detrol .................tolterodine Sedapap .............butalbital dicyclomine ..........Bentyl ziprasidone..............Geodon Ditropan .............oxybutinin Serentil ...............mesoridazine doxepin.................Sinequan zonisamide..............Zonegran Donnatal .............belladonna alkaloids* Seroquel .............quetiapine ethopropazine.......Parsidol ...........................and phenobarbital Sinequan ............doxepin fluphenazine .........Prolixin Elavil...................amitryptyline Stelazine .............trifluoperazine glycopyrrolate.......Robinul Eldepryl ..............selegiline Surmontil ...........trimipramine haloperidol............Haldol Enablex...............darifenacin Thorazine............chlorpromazine homotropine.........Homapin Esgic...................butalbital Tofranil ...............imipramine hyoscyamine ........Cystospaz, Eskalith...............lithium .............................Levsin, Levbid Etrafon................amitryptyline and Transderm-Scop.scopolamine imipramine ...........Tofranil ...........................perphenazine Trilafon ...............perphenazine lithium ..................Lithobid, Eskalith Fioricet ...............butabarbital VESIcare.............solifenacin mepenzolate .........Cantil Fiorinal ...............butabarbital Vivactil................protryptyline mesoridazine ........Serentil Fiortal .................butalbital Zonegran ............zonisamide methantreline........Banthine Geodon...............ziprasidone Zyprexa...............olanzapine mirtazapine...........Remeron Haldol .................haloperidol molindone ............Moban nortryptyline .........Pamelor, Aventyl olanzapine ............Zyprexa oxybutinin.............Ditropan *Belladonna alkaloids include atropine, hyoscyamine, and scopolamine 5/06 City of Milwaukee Health Department www.milwaukee.gov/health Tom Barrett, Mayor Bevan K. Baker, Commissioner of Health ¿Cómo puede ser afectada la Enfermedad de Calor por los Medicamentos? Ciertas medicaciones aumentan el riesgo de la Estas condiciones incluyen lo siguiente: Esta lista no es exhaustiva y es solamente una guía. enfermedad del calor (en inglés, "heat illness") • Demencia Otros medicamentos, incluyendo muchos diuréticos en interferir con la capacidad de sudar y de • Nausea o vómito (píldoras de agua) y antihistamínicos, con receta o refrescarse en su cuerpo (véase las listas • Enfermedad de Parkinson sin receta, también pueden aumentar el riesgo de la abajo). Esto puede conducir a disminuir la • Desórdenes psiquiátricos y emocionales como: enfermedad del calor. Se deben discutir otros tolerancia del calor y aumentar el riesgo de la Depresión (con o sin manía) problemas sobre la enfermedad con su profesional enfermedad del calor. Las personas que toma Esquizofrenia, desórdenes de ansiedad del cuidado de la salud. las medicaciones para ciertas condiciones • Convulsiones médicas pueden estar en un riesgo mayor de la • Espasmos estomacales, intestinales, de la vejiga Esta Lista de medicaciones fue desarrollada originalmente por la enfermedad del calor y debe tomar las medidas farmacia Osco y fue revisada por el Departamento de Salud de la Ciudad de Milwaukee con la ayuda del UW Escuela de Farmacia. preventivas necesarias. Lista por el NOMBRE GENERICO Lista por el NOMBRE de MARCA amitryptyline ........Elavil, Etrafon perphenazine...........Trilafon, Etrafon Abilify .................aripiprazole Homapin.............homotropine amoxapine ............Asendin phenelzine ...............Nardil Akineton .............biperiden Levbid.................hyoscyamine aripiprazole...........Abilify phenobarbital ..........Donnatal, Anafranil .............clomipramine Levsin.................hyoscyamine atropiney otros ................................Barbidonna, Artane.................trihexyphenidyl Lithobid ..............lithium ................................Bellaphen, etc. alcaloides de Asendin ..............amoxapine Mellaril ...............thioridazine belladonna* ..........B&O prochlorperazine .....Compazine Atapryl................selegiline Moban ................molindone .............................suppositories, propantheline ..........Pro-Banthine Aventyl................nortryptyline Nardil..................phenelzine .............................Barbidonna, protryptyline............Vivactil .............................Bellaphen, B&O Navane ...............thiothixene quetiapine ...............Seroquel .............................Donnatal, etc. suppositories......belladonna alkaloids* Norpramin ..........desipramine risperidone..............Risperdal benztropine...........Cogentin Banthine .............methantreline Pamelor..............nortryptyline scopolamine............Transderm-Scop biperiden ..............Akineton Barbidonna .........belladonna alkaloids* Parnate ...............tranylcypromine selegiline.................Eldepryl, ...........................y phenobarbital butabarbital ..........Butibel, Fiorinal, ................................Carbex, Parsidol ..............ethopropazine ............................. Bellaphen............belladonna alkaloids* Fioricet, ................................Atapryl Phrenilin .............butalbital .............................Pyridium Plus ...........................y
Load more

Recommended publications
  • Table 2. 2012 AGS Beers Criteria for Potentially
    Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May
    [Show full text]
  • Prochlorperazine 5Mg Tablets
    Package leaflet: Information for the patient Prochlorperazine 5mg tablets Read all of this leaflet carefully before you start taking this • the person is a child. This is because children may develop unusual face and body medicine, because it contains important information for you. movements (dystonic reactions) • Keep this leaflet. You may need to read it again. • you are diabetic or have high levels of sugar in your blood (hyperglycaemia). Your doctor • If you have any further questions, ask your doctor or pharmacist. may want to monitor you more closely. • This medicine has been prescribed for you only. Do not pass it on to If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before others. It may harm them, even if their signs of illness are the same taking Prochlorperazine Tablets. as yours. Other medicines and Prochlorperazine tablets • If you get any side effects, talk to your doctor or pharmacist. Tell your doctor or pharmacist if you are taking, have recently taken or might take any This includes any possible side effects not listed in this leaflet. other medicines. This includes medicines you buy without a prescription, including herbal See section 4. medicines. This is because Prochlorperazine Tablets can affect the way some other medicines work. What is in this leaflet: Also some medicines can affect the way Prochlorperazine Tablets work. 1 What Prochlorperazine tablets are and what they In particular, tell your doctor if you are taking any of the following: • medicines to help you sleep
    [Show full text]
  • HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Metabolic Changes: Atypical antipsychotic drugs have been associated with These highlights do not include all the information needed to use metabolic changes that may increase cardiovascular/cerebrovascular risk. CLOZARIL safely and effectively. See full prescribing information for These metabolic changes include: CLOZARIL. o Hyperglycemia and Diabetes Mellitus: Monitor for symptoms of CLOZARIL® (clozapine) tablets, for oral use hyperglycemia including polydipsia, polyuria, polyphagia, and Initial U.S. Approval: 1989 weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes. (5.9) WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC o Dyslipidemia: Undesirable alterations in lipids have occurred in HYPOTENSION, BRADYCARDIA, AND SYNCOPE; SEIZURE; patients treated with atypical antipsychotics. (5.9) MYOCARDITIS AND CARDIOMYOPATHY; INCREASED o Weight Gain: Significant weight gain has occurred. Monitor weight MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA- gain. (5.9) RELATED PSYCHOSIS • Neuroleptic Malignant Syndrome (NMS): Immediately discontinue and See full prescribing information for complete boxed warning. monitor closely. Assess for co-morbid conditions. (5.10) • Fever: Evaluate for infection and for neutropenia, NMS. (5.11) • Pulmonary Embolism (PE): Consider PE if respiratory distress, chest pain, • Severe Neutropenia: CLOZARIL can cause severe neutropenia, which or deep-vein thrombosis occur. (5.12) can lead to serious and fatal infections. Patients initiating and • Anticholinergic Toxicity: Use cautiously in presence of specific conditions continuing treatment with CLOZARIL must have a baseline blood (e.g., narrow angle glaucoma, use of anticholinergic drugs). (5.13) absolute neutrophil count (ANC) measured before treatment initiation • Interference with Cognitive and Motor Performance: Advise caution when and regular ANC monitoring during treatment (2.1, 5.1).
    [Show full text]
  • Minimum Laboratory Monitoring for Psychotropic Medications
    Minimum Laboratory Monitoring For Psychotropic Medications ANTIPSYCHOTIC MEDICATIONS GENERIC BRAND GENERIC BRAND Aripiprazole Abilify, Abilify Olanzapine Zyprexa, Zyprexa Zydis Maintena, Aristada Asenapine Saphris Paliperidone Invega, Invega Sustenna, Invega Trinza Brexpiprazole Rexulti Perphenazine Trilafon Cariprazine Vraylar Pimozide Orap Chlorpromazine Thorazine Quetiapine Seroquel, Seroquel XR Clozapine Clozaril, Fazaclo Risperidone Risperdal, Risperdal Consta, Risperdal M Tabs Fluphenazine, Fluphenazine D Prolixin, Prolixin D Thioridazine Mellaril Haloperidol, Haloperidol D Haldol, Haldol D Thiothixene Navane Iloperidone Fanapt Trifluoperazine Stelazine Loxapine Loxitane Ziprasidone Geodon Lurasidone Latuda MONITORING ANTIPSYCHOTIC FREQUENCY OF MONITORING AIMS (Abnormal Involuntary Movement Scale) On initiation of any antipsychotic medication and at least every six months thereafter, or more frequently as clinically indicated. ABDOMINAL GIRTH (>18 years old) For individuals at least 18 years old, on initiation of any medication and at least every six months thereafter, or more frequently as clinically indicated. WEIGHT & BODY MASS INDEX (BMI) On initiation of any medication and at least every six months thereafter, or more frequently as clinically indicated. HEART RATE & BLOOD PRESSSURE On initiation of any medication and at least every six months thereafter, or more frequently as clinically indicated. COMPREHENSIVE METABOLIC PANEL (CMP), On initiation of any medication affecting this parameter and at least annually LIPIDS, FASTING
    [Show full text]
  • Anticholinergic Drugs Improve Symptoms but Increase Dry Mouth in Adults with Overactive Bladder Syndrome
    Source of funding: Evid Based Nurs: first published as 10.1136/ebn.6.2.49 on 1 April 2003. Downloaded from Review: anticholinergic drugs improve symptoms but Health Research Council of Aotearoa increase dry mouth in adults with overactive bladder New Zealand. syndrome For correspondence: Jean Hay-Smith, Hay-Smith J, Herbison P,Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Dunedin School of Cochrane Database Syst Rev 2002;(3):CD003781 (latest version May 29 2002). Medicine, University of Otago, Dunedin, New QUESTION: What are the effects of anticholinergic drugs in adults with overactive Zealand. jean.hay-smith@ bladder syndrome? otago.ac.nz Data sources Parallel arm studies of anticholinergic drugs v placebo for overactive bladder syndrome in Studies were identified by searching the Cochrane adults at 12 days to 12 weeks* Incontinence Group trials register (to January 2002) Weighted event rates and reference lists of relevant papers. Anticholinergic Study selection Outcomes drugs Placebo RBI (95% CI) NNT (CI) Randomised or quasi-randomised controlled trials in Self reported cure or adults with symptomatic diagnosis of overactive bladder improvement (8 studies) 63% 45% 41% (29 to 54) 6 (5 to 8) syndrome, urodynamic diagnosis of detrusor overactiv- RRI (CI) NNH (CI) ity, or both, that compared an anticholinergic drug Dry mouth (20 studies) 36% 15% 138 (70 to 232) 5 (4 to 7) (given to decrease symptoms of overactive bladder) with Outcomes Weighted mean difference (CI) placebo or no treatment. Studies of darifenacin, emepronium bromide or carrageenate, dicyclomine Number of leakage episodes in 24 hours (9 − chloride, oxybutynin chloride, propiverine, propanthe- studies) 0.56 (–0.73 to –0.39) Number of micturitions in 24 hours (8 studies) −0.59 (–0.83 to –0.36) line bromide, tolterodine, and trospium chloride were Maximum cystometric volume (ml) (12 studies) 54.3 (43.0 to 65.7) included.
    [Show full text]
  • Medication Conversion Chart
    Fluphenazine FREQUENCY CONVERSION RATIO ROUTE USUAL DOSE (Range) (Range) OTHER INFORMATION KINETICS Prolixin® PO to IM Oral PO 2.5-20 mg/dy QD - QID NA ↑ dose by 2.5mg/dy Q week. After symptoms controlled, slowly ↓ dose to 1-5mg/dy (dosed QD) Onset: ≤ 1hr 1mg (2-60 mg/dy) Caution for doses > 20mg/dy (↑ risk EPS) Cmax: 0.5hr 2.5mg Elderly: Initial dose = 1 - 2.5mg/dy t½: 14.7-15.3hr 5mg Oral Soln: Dilute in 2oz water, tomato or fruit juice, milk, or uncaffeinated carbonated drinks Duration of Action: 6-8hr 10mg Avoid caffeinated drinks (coffee, cola), tannics (tea), or pectinates (apple juice) 2° possible incompatibilityElimination: Hepatic to inactive metabolites 5mg/ml soln Hemodialysis: Not dialyzable HCl IM 2.5-10 mg/dy Q6-8 hr 1/3-1/2 po dose = IM dose Initial dose (usual): 1.25mg Onset: ≤ 1hr Immediate Caution for doses > 10mg/dy Cmax: 1.5-2hr Release t½: 14.7-15.3hr 2.5mg/ml Duration Action: 6-8hr Elimination: Hepatic to inactive metabolites Hemodialysis: Not dialyzable Decanoate IM 12.5-50mg Q2-3 wks 10mg po = 12.5mg IM CONVERTING FROM PO TO LONG-ACTING DECANOATE: Onset: 24-72hr (4-72hr) Long-Acting SC (12.5-100mg) (1-4 wks) Round to nearest 12.5mg Method 1: 1.25 X po daily dose = equiv decanoate dose; admin Q2-3wks. Cont ½ po daily dose X 1st few mths Cmax: 48-96hr 25mg/ml Method 2: ↑ decanoate dose over 4wks & ↓ po dose over 4-8wks as follows (accelerate taper for sx of EPS): t½: 6.8-9.6dy (single dose) ORAL DECANOATE (Administer Q 2 weeks) 15dy (14-100dy chronic administration) ORAL DOSE (mg/dy) ↓ DOSE OVER (wks) INITIAL DOSE (mg) TARGET DOSE (mg) DOSE OVER (wks) Steady State: 2mth (1.5-3mth) 5 4 6.25 6.25 0 Duration Action: 2wk (1-6wk) Elimination: Hepatic to inactive metabolites 10 4 6.25 12.5 4 Hemodialysis: Not dialyzable 20 8 6.25 12.5 4 30 8 6.25 25 4 40 8 6.25 25 4 Method 3: Admin equivalent decanoate dose Q2-3wks.
    [Show full text]
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • Management of Side Effects of Antipsychotics
    Management of side effects of antipsychotics Oliver Freudenreich, MD, FACLP Co-Director, MGH Schizophrenia Program www.mghcme.org Disclosures I have the following relevant financial relationship with a commercial interest to disclose (recipient SELF; content SCHIZOPHRENIA): • Alkermes – Consultant honoraria (Advisory Board) • Avanir – Research grant (to institution) • Janssen – Research grant (to institution), consultant honoraria (Advisory Board) • Neurocrine – Consultant honoraria (Advisory Board) • Novartis – Consultant honoraria • Otsuka – Research grant (to institution) • Roche – Consultant honoraria • Saladax – Research grant (to institution) • Elsevier – Honoraria (medical editing) • Global Medical Education – Honoraria (CME speaker and content developer) • Medscape – Honoraria (CME speaker) • Wolters-Kluwer – Royalties (content developer) • UpToDate – Royalties, honoraria (content developer and editor) • American Psychiatric Association – Consultant honoraria (SMI Adviser) www.mghcme.org Outline • Antipsychotic side effect summary • Critical side effect management – NMS – Cardiac side effects – Gastrointestinal side effects – Clozapine black box warnings • Routine side effect management – Metabolic side effects – Motor side effects – Prolactin elevation • The man-in-the-arena algorithm www.mghcme.org Receptor profile and side effects • Alpha-1 – Hypotension: slow titration • Dopamine-2 – Dystonia: prophylactic anticholinergic – Akathisia, parkinsonism, tardive dyskinesia – Hyperprolactinemia • Histamine-1 – Sedation – Weight gain
    [Show full text]
  • Drugs to Avoid in Patients with Dementia
    Detail-Document #240510 -This Detail-Document accompanies the related article published in- PHARMACIST’S LETTER / PRESCRIBER’S LETTER May 2008 ~ Volume 24 ~ Number 240510 Drugs To Avoid in Patients with Dementia Elderly people with dementia often tolerate drugs less favorably than healthy older adults. Reasons include increased sensitivity to certain side effects, difficulty with adhering to drug regimens, and decreased ability to recognize and report adverse events. Elderly adults with dementia are also more prone than healthy older persons to develop drug-induced cognitive impairment.1 Medications with strong anticholinergic (AC) side effects, such as sedating antihistamines, are well- known for causing acute cognitive impairment in people with dementia.1-3 Anticholinergic-like effects, such as urinary retention and dry mouth, have also been identified in drugs not typically associated with major AC side effects (e.g., narcotics, benzodiazepines).3 These drugs are also important causes of acute confusional states. Factors that may determine whether a patient will develop cognitive impairment when exposed to ACs include: 1) total AC load (determined by number of AC drugs and dose of agents utilized), 2) baseline cognitive function, and 3) individual patient pharmacodynamic and pharmacokinetic features (e.g., renal/hepatic function).1 Evidence suggests that impairment of cholinergic transmission plays a key role in the development of Alzheimer’s dementia. Thus, the development of the cholinesterase inhibitors (CIs). When used appropriately, the CIs (donepezil [Aricept], rivastigmine [Exelon], and galantamine [Razadyne, Reminyl in Canada]) may slow the decline of cognitive and functional impairment in people with dementia. In order to achieve maximum therapeutic effect, they ideally should not be used in combination with ACs, agents known to have an opposing mechanism of action.1,2 Roe et al studied AC use in 836 elderly patients.1 Use of ACs was found to be greater in patients with probable dementia than healthy older adults (33% vs.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Management of Major Depressive Disorder Clinical Practice Guidelines May 2014
    Federal Bureau of Prisons Management of Major Depressive Disorder Clinical Practice Guidelines May 2014 Table of Contents 1. Purpose ............................................................................................................................................. 1 2. Introduction ...................................................................................................................................... 1 Natural History ................................................................................................................................. 2 Special Considerations ...................................................................................................................... 2 3. Screening ........................................................................................................................................... 3 Screening Questions .......................................................................................................................... 3 Further Screening Methods................................................................................................................ 4 4. Diagnosis ........................................................................................................................................... 4 Depression: Three Levels of Severity ............................................................................................... 4 Clinical Interview and Documentation of Risk Assessment...............................................................
    [Show full text]